BeiGene - BGNE Stock Forecast, Price & News

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

A number of research firms have weighed in on BGNE. JPMorgan Chase & Co. reissued an "overweight" rating and set a $296.00 target price on shares of BeiGene in a report on Tuesday, August 9th. StockNews.com raised shares of BeiGene from a "sell" rating to a "hold" rating in a report on Monday, August 8th. Finally, Morgan Stanley lowered their price target on BeiGene from $300.00 to $293.00 and set an "overweight" rating for the company in a research report on Friday, July 15th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $299.25.

BeiGene Stock Performance

Shares of BeiGene stock traded down $4.15 during trading hours on Friday, hitting $173.68. 278 shares of the company's stock traded hands, compared to its average volume of 222,454. BeiGene has a 12-month low of $118.18 and a 12-month high of $426.56. The stock has a market capitalization of $17.97 billion, a price-to-earnings ratio of -8.71 and a beta of 0.66. The company has a fifty day simple moving average of $172.22 and a 200-day simple moving average of $175.98. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.54 and a quick ratio of 4.35.

Insider Buying and Selling

In other BeiGene news, COO Xiaobin Wu sold 3,410 shares of the firm's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $141.99, for a total value of $484,185.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other BeiGene news, COO Xiaobin Wu sold 3,410 shares of the stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $141.99, for a total transaction of $484,185.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Julia Aijun Wang sold 295 shares of the business's stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,740 shares of company stock valued at $1,124,135. 7.50% of the stock is owned by company insiders.